Ajinomoto Co., Ltd.

Manabu Kitazawa

Keiji Iwasaki

Satoru Ohashi

Yoko Kuriyama

Satoru Okamoto

Kazutami Sakamoto

Sho Senda

Nao Sugimoto

Eiji Shiojiri

Ikue Harata

Toshihide Kamata

Sei Uemura

Tomomi Yoshida

Yoshinori Wada

Takashi Nakano

Hideki Matsumoto

Yasuhiko Tabata

Yoshihiro Kobayashi

Toshihiko Yoshimura

Masayuki Sugiki

Daisuke Ejima

Naoyuki Fukuchi

Munetaka Tokumasu

Masayo Date

Mitsuo Takahashi

Yoko Masuzawa

Yoichiro Shima

Takuya Matsumoto

Hiroyasu Koto

Yasunobu Noguchi

Hideki Yoshihara

Haruko Hirashima

Akiko Oonuki

Haruna Sato

Yuichi Watanabe

Yumi Ando

Takayoshi Fujii

Kousaku Ohkawa

Yasuko Nogi

Culture media, which contain albumin carrying a reduced amount of fatty acid, are useful for culturing stem cells.

Medium for culturing stem cells

Cultivating a pluripotent stem cell in a medium comprising at least one member selected from the group consisting of ethanolamine, an ethanolamine analog, and a pharmaceutically acceptable salt thereof, and which is substantially free of &#x3b2;-mercaptoethanol or contains &#x3b2;-mercaptoethanol at a concentration of not more than 9 &#x3bc;M, and the like, is effective for the proliferation of a pluripotent stem cell while maintaining an undifferentiated state.

Culture method for stable proliferation of pluripotent stem cell while maintaining undifferentiated state

A medium which comprises a fibroblast growth factor (FGF), and a sulfated compound or a pharmaceutically acceptable salt thereof at a concentration which promotes the growth of a stem cell in the presence of FGF, is useful for culturing stem cells.

Culture medium for proliferating stem cell, which contains sulfated compound

Culture media which contain a water-soluble polymer, such as polyvinyl alcohol and the like, and albumin, and the like, are useful for the proliferation of stem cells, and show good culture results, particularly with iPS cells, and maintain the stability of the medium properties, as well as using a reduced amount of albumin.

Medium for stem cell use

A membrane switch in which a first conductive part is formed on a first substrate, a second conductive part is formed on a second substrate, and the substrates are layered via a spacer such that the conductive parts face each other with a space therebetween, and an organic material showing piezoelectricity is filled, or disposed in the space such that an air gap is present, are useful for obtaining an output signal corresponding to an applied pressure.

Membrane switch and object employing same

Ferroelectric memory elements which contain a poly &#x3b1;-amino acid which is a copolymer containing a glutamic acid-&#x3b3;-ester unit represented by the formula (I), defined herein, and a glutamic acid-&#x3b3;-ester unit represented by the formula (II), defined herein, in a molar ratio of units of formula (I) to units of formula (II) of 10/90-90/10 are useful as recording elements such as RFID and the like.

Poly &#x3b1;-amino acid and ferroelectric memory element using same

Poly(&#x3b1;-amino acid) which contain: (A) a glutamic acid &#x3b3;-ester unit represented by formula (I): and (B) one or more kinds of units selected from a glutamic acid &#x3b3;-ester unit represented by formula (II), an alanine unit, a phenylalanine unit and an N-benzyloxycarbonyllysine unit, represented by formula (III), and a glutamic acid &#x3b3;-ester unit represented by formula (IV) can be dissolved in various solvents and are useful for preparing piezoelectric elements which exhibit superior piezoelectricity.

Piezoelectric element

The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.

Medical material and method for manufacturing same

The present invention provides a novel compound having a kininogenase-inhibitory action and its pharmaceutical use. The compounds are represented by the formulas (A), (B), (C), (E) and (H): wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof.

Aniline derivatives

Objects of the present invention are to provide an oxidative stress inhibitor which is capable of suppressing the expression of a cytotoxic protein and the activation of a gene transcriptional regulatory factor taking part such expression of a cytotoxic protein and exhibits good feeling upon use and safety; to provide a method for preventing, retarding, alleviating or treating a skin change due to aging or an undesirable aesthetic skin change, both caused or promoted by an oxidative stress; and to provide a cosmetic composition or dermatologic preparation for external use comprising the oxidative stress inhibitor as an effective ingredient, and for those purposes are employed an oxidative stress inhibiting agent which comprises, as an effective ingredient, at least one selected from cysteine or cystine derivatives and the salts thereof.

Cysteine derivatives

The present invention provides cystine derivatives, which may be in a free form, a salt form, a solvate form. The cystine derivatives of the present invention may be used to suppress activation of inflammatory factors. Accordingly, the present invention provides: compositions containing the cystine derivatives; a method for suppressing the activation of inflammatory factors by administering the composition; a method for preventing, ameliorating and/or therapeutically treating diseases, skin injuries or disorders involved in the activation of inflammatory factors by administering the composition; a method for preventing, delaying, ameliorating and/or therapeutically treating skin change via aging or aesthetically unfavorable skin change as induced or promoted by inflammatory factors by administering the composition; and pharmaceutical agents containing the cystine derivatives.

Cystine derivative and agent for suppressing activation of inflammatory factors

Growing community of inventors

Kawasaki, Japan

Manabu Kitazawa